U-shaped relationship between urea level and hepaticU-shaped relationship between urea level and hepatic decompensation in chronic liver diseases decompensation in chronic liver diseases = U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases

다국어 초록 (Multilingual Abstract)

Background/Aims: We aimed to determine the association between blood urea level and incident cirrhosis, hepatic decompensation, and hepatocellular carcinoma in chronic liver disease (CLD) patients.
Methods: The association between blood urea level and liver fibrosis/liver-related events were evaluated on continuous scale with restricted cubic spline curves based on generalized additive model or Cox proportional hazards models. Then, the above associations were evaluated by urea level within intervals.
Results: Among 4,282 patients who had undergone liver stiffness measurement (LSM) by transient elastography, baseline urea level had a U-shaped association with LSM and hepatic decompensation development after a median follow-up of 5.5 years. Compared to patients with urea of 3.6–9.9 mmol/L, those with urea ≤3.5 mmol/L (adjusted hazard ratio [aHR], 4.15; 95% confidence interval [CI], 1.68–10.24) and ≥10 mmol/L (aHR, 5.22; 95% CI, 1.86–14.67) had higher risk of hepatic decompensation. Patients with urea ≤3.5 mmol/L also had higher risk of incident cirrhosis (aHR, 3.24; 95% CI, 1.50–6.98). The association between low urea level and incident cirrhosis and hepatic decompensation was consistently observed in subgroups by age, gender, albumin level, and comorbidities. The U-shaped relationship between urea level and LSM was validated in another population screening study (n=917). Likewise, urea ≤3.5 mmol/L was associated with a higher risk of incident cirrhosis in a territory-wide cohort of 12,476 patients with nonalcoholic fatty liver disease at a median follow-up of 9.9 years (aHR, 1.27; 95% CI, 1.03–1.57).
Conclusions: We identified a U-shaped relationship between the urea level and liver fibrosis/incident cirrhosis/hepatic decompensation in patients with CLD.

참고문헌 (Reference)

1 De Chiara F, "Urea cycle dysregulation in non-alcoholic fatty liver disease" 69 : 905-915, 2018

2 Lee JS, "Urea cycle dysregulation generates clinically relevant genomic and biochemical signatures" 174 : 1559-1570, 2018

3 Vilstrup H, "Synthesis of urea after stimulation with amino acids : relation to liver function" 21 : 990-995, 1980

4 Ginès P, "Renal failure in cirrhosis" 361 : 1279-1290, 2009

5 Liu K, "Prognostic value of controlled attenuation parameter by transient elastography" 112 : 1812-1823, 2017

6 Wong VW, "Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese : a population study using protonmagnetic resonance spectroscopy and transient elastography" 61 : 409-415, 2012

7 Lee DH, "Predicted lean body mass, fat mass, and all cause and cause specific mortality in men : prospective US cohort study" 362 : k2575-, 2018

8 Yip TC, "On-treatment improvement of MELD score reduces death and hepatic events in patients with hepatitis B-related cirrhosis" 113 : 1629-1638, 2018

9 Wong VW, "Noninvasive biomarkers in NAFLD and NASH-current progress and future promise" 15 : 461-478, 2018

10 Eriksen PL, "Non-alcoholic fatty liver disease alters expression of genes governing hepatic nitrogen conversion" 39 : 2094-2101, 2019

11 Tsochatzis EA, "Liver cirrhosis" 383 : 1749-1761, 2014

12 Foster GR, "Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis" 64 : 1224-1231, 2016

13 Lee HW, "Hepatic decompensation in cirrhotic patients receiving antiviral therapy for chronic hepatitis B" 19 : 1950-1958, 2021

14 Wanlong Wu, "Forced vital capacity predicts the survival of interstitial lung disease in anti-MDA5 positive dermatomyositis: a multi-centre cohort study" Oxford University Press (OUP) 61 (61): 230-239, 2021

15 Thomsen KL, "Experimental nonalcoholic steatohepatitis compromises ureagenesis, an essential hepatic metabolic function" 307 : G295-G301, 2014

16 Younossi ZM, "Epidemiology of chronic liver diseases in the USA in the past three decades" 69 : 564-568, 2020

17 Laursen TL, "Early normalization of reduced urea synthesis capacity after direct-acting antiviral therapy in hepatitis C cirrhosis" 319 : G151-G156, 2020

18 Pundir CS, "Determination of urea with special emphasis on biosensors : a review" 123 : 36-50, 2019

19 Boursier J, "Determination of reliability criteria for liver stiffness evaluation by transient elastography" 57 : 1182-1191, 2013

20 Salazar MC, "Association of delayed adjuvant chemotherapy with survival after lung cancer surgery" 3 : 610-619, 2017

21 De Chiara F, "Ammonia scavenging prevents progression of fibrosis in experimental nonalcoholic fatty liver disease" 71 : 874-892, 2020

22 Glavind E, "Alcoholic hepatitis markedly decreases the capacity for urea synthesis" 11 : e0158388-, 2016

23 Bernardi M, "Albumin in decompensated cirrhosis : new concepts and perspectives" 69 : 1127-1138, 2020

24 Calzadilla-Bertot L, "ABIDE : an accurate predictive model of liver decompensation in patients with nonalcoholic fatty liver-related cirrhosis" 73 : 2238-2250, 2021